A Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer

Starting soon · Not applicable

Conditions studied: Breast Cancer

In brief

For locally advanced or recurrent metastatic breast cancer that is resistant to systemic therapy, radiotherapy (RT) may be considered as the preferred treatment option when the lesion is unresectable, or the patient is not suitable for surgery. This study aim to evelatuate the local control of radical dose RT or new RT technique (such as patially fractionated radiation therapy, SFRT) for the locally advanced or recurrent metastatic breast cancer.

Key facts

Study ID

NCT07672743

Run by

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

People needed

29

Starts

2026-06-30

Expected to finish

2027-12-31

Last updated by the study team

2026-06-29

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
• Locally advanced or recurrent metastatic breast cancer, pathologically confirmed;
• At least one extracranial measurable lesion suitable for radiotherapy;
• Signature of informed consent form.

You may not qualify if…

• Pregnant or lactation women;
• Severe concomitant conditions, including persistent or active infections, symptomatic congestive heart failure, unstable angina pectoris, and serious arrhythmias et al.

Where it is running

• Cancer Hospital, Chinese Academy of Medical Sciences — Beijing, Beijing Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.